set to the default values. The adjustable parameters are set with the following values: overlap span =1, overlap fraction = 0.125, word threshold (T) = 11. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity. A % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region. The "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored). --

In the paragraph on page 31, lines 1-15, the text has been amended as follows:

It may be desired to purify UCP4 from recombinant cell proteins or The following procedures are exemplary of suitable polypeptides. purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, SEPHADEX™ G-75; protein A SEPHAROSE™ columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the UCP4. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, <u>Protein Purification</u>: Principles and Practice, Springer-Verlag, New York (1982). purification step(s) selected will depend, for example, on the nature of the production process used and the particular UCP4 produced. --

In the paragraph on page 48, lines 3-13, the text has been amended as follows:

⁻⁻ EST databases, which included public EST databases (e.g., GENBANK™), and a proprietary EST database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA), were searched for sequences having homologies to human UCP3.